Inclusion Criteria:

          -  Patients must have histologically confirmed solid tumor that is metastatic or
             unresectable and for which standard curative or palliative measures do not exist or
             are no longer effective

          -  Patients must have evaluable disease or disease measurable per Response Evaluation
             Criteria in Solid Tumors (RECIST) version 1.1; measurable disease is defined as at
             least one dimension (longest diameter to be recorded for non-nodal lesions and short
             axis for nodal lesions) as >= 20 mm (>= 2 cm) with conventional techniques or as >= 10
             mm (>= 1 cm) with spiral computed tomography (CT) scan, magnetic resonance imaging
             (MRI), or calipers by clinical exam

          -  There are no limits on prior lines of therapy; however, patients must have recovered
             to eligibility levels from prior toxicity or adverse events as a result of previous
             treatment prior to entering the study (except alopecia)

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  Life expectancy of greater than 3 months

          -  Absolute neutrophil count >= 1,500/microliters

          -  Platelets >= 100,000/microliters

          -  Total bilirubin =< 1.5 X institutional upper limit of normal

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             =< 2.5 X institutional upper limit of normal

          -  Creatinine < 1 X institutional upper limit of normal OR creatinine clearance >= 50
             mL/min determined by Cockcroft-Gault formula

          -  Creatine phosphokinase =< institutional upper limit of normal

          -  The effects of onalespib and AT7519M on the developing human fetus are unknown; for
             this reason, women of childbearing potential and male patients with partners of
             childbearing potential must agree to use adequate contraception (hormonal or barrier
             method of birth control or abstinence) prior to study entry, for the duration of study
             participation, and for 2 months after completion of study; should a woman become
             pregnant or suspect she is pregnant while she or her partner is participating in this
             study, she should inform her treating physician immediately; women of childbearing
             potential enrolling on study must have a negative pregnancy test within 72 hours of
             enrollment in order to be eligible; because there is an unknown but potential risk to
             nursing infants secondary to treatment of the mother with onalespib and AT7519M,
             breastfeeding should be discontinued while the mother is treated with onalespib and
             AT7519M

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Patients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for
             nitrosoureas or mitomycin C) prior to entering the study; patients who have had prior
             onalespib or AT7519M as a monotherapy will not be excluded

          -  Patients who are receiving any other investigational agents

          -  Patients with known brain metastases or carcinomatous meningitis are excluded from
             this clinical trial, with the exception of patients with brain metastatic disease that
             has previously been treated and remained stable on MRI >= 2 months after treatment,
             without steroids or anti-epileptic medications; these patients may be enrolled at the
             discretion of the principal investigator

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to onalespib or AT7519M

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements; additionally, patients with other co-morbid disease or metabolic
             dysfunction that would render the subject at high risk for treatment complications may
             be excluded at the discretion of the principal investigator in the interest of patient
             safety

          -  The effects of onalespib and AT7519M on the developing human fetus are unknown; for
             this reason, pregnant women are excluded from this study

          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral
             therapy known to interact with CYP isoenzymes are ineligible; in addition, HIV
             patients with CD4 count < 200 cells/uL are ineligible; appropriate studies will be
             undertaken in patients receiving combination antiretroviral therapy when indicated

          -  Consistent corrected QT (QTc) > 450 msec for men and > 470 msec for women by
             Fridericia formula, on 3 separate electrocardiograms (ECGs); patients with a history
             of long QTc syndrome or personal or family history of ventricular arrhythmias will be
             excluded

          -  Patients with pre-existing retinal disease on ophthalmologic exam will be excluded due
             to potential eye toxicities known to be associated with onalespib

          -  Patients with left ventricular ejection fraction < 50% on echocardiogram or multigated
             acquisition scan will be excluded based on known cardiotoxicities associated with
             onalespib

          -  Patients with grade >= 2 peripheral neuropathy will not be permitted on study